Prasugrel hydrochloride for the treatment of acute coronary syndrome patients

References

• BMJ. Overview of acute coronary syndrome. 2016 [cited 2015 Oct 1]. Available from: http://bestpractice.bmj.com/best-practice/monograph/152.html
   Google Scholar
• Peters RJ, Mehta S, Yusuf S. Acute coronary syndromes without ST segment elevation. BMJ. 2007 Jun 16;334(7606):1265–1269.
   PubMed Web of Science ®Google Scholar
• Authors/Task Force Members, Roffi M, Patrono C, Collet JP, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2015 Aug 29. pii: ehv407. [Epub ahead of print].
   PubMedGoogle Scholar
• Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol. 2012 Jul 17;60(3):193–199.
   PubMed Web of Science ®Google Scholar
• Schulz S, Angiolillo DJ, Antoniucci D, et al. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy–design and rationale of the iNtracoronary stenting and antithrombotic regimen: rapid early action for coronary treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res. 2014 Feb;7(1):91–100.
   PubMed Web of Science ®Google Scholar
• Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation. 2016 Aug 30;116:024823.
   Google Scholar
• European Medicines Agency. Evaluation of medicines for human use. Assess Rep Efient. 2009;117561.
   Google Scholar
• Ancrenaz V, Daali Y, Fontana P, et al. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab. 2010 Oct;11(8):667–677.
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010 Jan;38(1):92–99.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22;360(4):354–362.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Press Release. FDA announces new boxed warning on plavix. 2010.
   Google Scholar
• Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy. 2009 Sep;29(9):1089–1102.
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006 Mar;47(3):377–384.
   PubMed Web of Science ®Google Scholar
• Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000 Apr;129(7):1439–1446.
   PubMed Web of Science ®Google Scholar
• Savcic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25(Suppl 2):15–19.
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Payne CD, Weerakkody GJ, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol. 2007 Mar;49(3):167–173.
   PubMed Web of Science ®Google Scholar
• Matsushima N, Jakubowski JA, Asai F, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. Platelets. 2006 Jun;17(4):218–226.
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007 Jan;153(1):66.e9-66.16.
   PubMed Web of Science ®Google Scholar
• Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006 May;27(10):1166–1173.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005 Jun 28;111(25):3366–3373.
   PubMed Web of Science ®Google Scholar
• Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol. 2012 Jun 12;59(24):2159–2164.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001–2015.
   Google Scholar
• Erlinge D, Gurbel PA, James S, et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol. 2013 Aug 13;62(7):577–583.
   PubMed Web of Science ®Google Scholar
• Erlinge D, Ten Berg J, Foley D, et al. Reduction in platelet reactivity with Prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol. 2012 Nov 13;60(20):2032–2040.
   PubMed Web of Science ®Google Scholar
• Silvain J, Cayla G, Hulot J-S, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J. 2012;33:1241–1249.
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012 Oct 4;367(14):1297–1309.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013 Sep 12;369(11):999–1010.
   PubMed Web of Science ®Google Scholar
• Brener SJ, Oldroyd KG, Maehara A, et al. Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). Am J Cardiol. 2014 May 1;113(9):1457–1460.
   PubMed Web of Science ®Google Scholar
• Zeymer U, Mochmann HC, Mark B, et al. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction). JACC Cardiovasc Interv. 2015 Jan;8(1Pt B):147–154.
   PubMed Web of Science ®Google Scholar
• Bae JP, Faries DE, Ernst FR, et al. Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. Curr Med Res Opin. 2014 Nov;30(11):2207–2216.
   PubMed Web of Science ®Google Scholar
• Baber U, Sartori S, Aquino M, et al. 90-Day effectiveness and safety of prasugrel vs. clopidogrel as used in clinical practice in patients with ACS undergoing PCI: Initial findings from the PROMETHEUS study. In: SCAI Late Breaking Clinical Trial presentation, San Diego, 2015.
   Google Scholar
• Kurz DJ, Radovanovic D, Seifert B, et al. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: a propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-plus registry. Eur Heart J Acute Cardiovasc Care. 2015 Jan 22;5(1).
   PubMed Web of Science ®Google Scholar
• Yasuda H, Yamada M, Sawada S, et al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Intern Med. 2009;48(19):1725–1730.
   PubMed Web of Science ®Google Scholar
• Boustiere C, Veitch A, Vanbiervliet G, et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2011 May;43(5):445–461.
   PubMed Web of Science ®Google Scholar
• Parodi G, Bellandi B, Venditti F, et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol. 2012 Jan 15;109(2):214–218.
   PubMed Web of Science ®Google Scholar
• Maseneni S, Donzelli M, Brecht K, et al. Toxicity of thienopyridines on human neutrophil granulocytes and lymphocytes. Toxicology. 2013 Jun 7;308:11–19.
   PubMed Web of Science ®Google Scholar
• Jacob S, Dunn BL, Qureshi ZP, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov;38(8):845–853.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT investigators. Evaluation of platelet IIb/IIIa Inhibitor for stenting. JAMA. 1999 Mar 3;281(9):806–810.
   PubMed Web of Science ®Google Scholar
• Neuman MG, Malkiewicz IM, Shear NH. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem. 2000 Oct;33(7):517–524.
   PubMed Web of Science ®Google Scholar
• Deshmukh AJ, Pant S, Cook J, et al. Prasugrel-induced rash. Ann Pharmacother. 2012 Jul-Aug;46(7–8):1123–1125.
   PubMed Web of Science ®Google Scholar
• Mutnick JL. Desensitization to prasugrel: cardiology’s increased need for allergy consultation. Ann Allergy Asthma Immunol. 2012 Feb;108(2):124–125.
   PubMed Web of Science ®Google Scholar
• Raccah BH, Shalit M, Danenberg HD. Allergic reaction to prasugrel and cross-reactivity with clopidogrel. Int J Cardiol. 2012 Jun 14;157(3):e48–9.
   Google Scholar
• Peppard SR, Held-Godgluck BM, Beddingfield R. Use of prasugrel in a patient with clopidogrel hypersensitivity. Ann Pharmacother. 2011 Oct;45(10):e54.
   Google Scholar
• Cattaneo M. Prasugrel and cancer. Arch Intern Med. 2010 Nov 22;170(21):1944.
   PubMedGoogle Scholar
• Serebruany V, Floyd J, Chew D. Excess of solid cancers after prasugrel: the food and drug administration outlook. Am J Ther. 2010 Jul 10. [Epub ahead of print].
   Google Scholar
• Serebruany VL. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens? Fundam Clin Pharmacol. 2009 Aug;23(4):411–417.
   PubMed Web of Science ®Google Scholar
• Nanau RM, Delzor F, Neuman MG. Efficacy and safety of prasugrel in acute coronary syndrome patients. Clin Biochem. 2014 May;47(7–8):516–528.
   PubMed Web of Science ®Google Scholar
• Task Force on the Management of ST-segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569–2619.
   PubMed Web of Science ®Google Scholar
• Floyd JS, Serebruany VL. Prasugrel as a potential cancer promoter: review of the unpublished data. Arch Intern Med. 2010 Jun 28;170(12):1078–1080.
   PubMedGoogle Scholar
• NICE. Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes. Technology appraisal guidance [TA317]. 2014.
   Google Scholar
• NICE. Myocardial infarction with ST-segment elevation: acute management. Clinical guideline [CG167]. 2013.
   Google Scholar
• NICE. Unstable angina and NSTEMI: early management. Clinical guideline [CG94]. 2010.
   Google Scholar
• Gunarathne A, Alahmar A, Gershlick AH. Data supporting the use of the radial approach as the default strategy in octogenarians undergoing primary-PCI? Int JCardiol. 2016 1;208:60–64.
   PubMed Web of Science ®Google Scholar